About: A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses
Creator	Xia, Xianzhu Yang, Songtao Zhang, Ying Wong, Gary Chi, Hang Feng, Na Gao, Yuwei Wang, Hualei Wang, Tiecheng Zhao, Yongkun Zhang, Shengnan Mo, Ruo Yan, Feihu Wu, Fangfang
Source	PMC
abstract	Ebola virus infections lead to severe hemorrhagic fevers in humans and nonhuman primates; and human fatality rates are as high as 67%–90%. Since the Ebola virus was discovered in 1976, the only available treatments have been medical support or the emergency administration of experimental drugs. The absence of licensed vaccines and drugs against the Ebola virus impedes the prevention of viral infection. In this study, we generated recombinant baculoviruses (rBV) expressing the Sudan virus (SUDV) matrix structural protein (VP40) (rBV-VP40-VP40) or the SUDV glycoprotein (GP) (rBV-GP-GP), and SUDV virus-like particles (VLPs) were produced by co-infection of Sf9 cells with rBV-SUDV-VP40 and rBV-SUDV-GP. The expression of SUDV VP40 and GP in SUDV VLPs was demonstrated by IFA and Western blot analysis. Electron microscopy results demonstrated that SUDV VLPs had a filamentous morphology. The immunogenicity of SUDV VLPs produced in insect cells was evaluated by the immunization of mice. The analysis of antibody responses showed that mice vaccinated with SUDV VLPs and the adjuvant Montanide ISA 201 produced SUDV GP-specific IgG antibodies. Sera from SUDV VLP-immunized mice were able to block infection by SUDV GP pseudotyped HIV, indicating that a neutralizing antibody against the SUDV GP protein was produced. Furthermore, the activation of B cells in the group immunized with VLPs mixed with Montanide ISA 201 was significant one week after the primary immunization. Vaccination with the SUDV VLPs markedly increased the frequency of antigen-specific cells secreting type 1 and type 2 cytokines. To study the therapeutic effects of SUDV antibodies, horses were immunized with SUDV VLPs emulsified in Freund’s complete adjuvant or Freund’s incomplete adjuvant. The results showed that horses could produce SUDV GP-specific antibodies and neutralizing antibodies. These results showed that SUDV VLPs demonstrate excellent immunogenicity and represent a promising approach for vaccine development against SUDV infection. Further, these horse anti-SUDV purified immunoglobulins lay a foundation for SUDV therapeutic drug research.
has issue date	2020-01-03(xsd:dateTime)
bibo:doi	10.3390/v12010064
bibo:pmid	31947873
has license	cc-by
sha1sum (hex)	2530bf775255e8026438e91645aba95d0506928e
schema:url	https://doi.org/10.3390/v12010064
resource representing a document's title	A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses
has PubMed Central identifier	PMC7019897
has PubMed identifier	31947873
schema:publication	Viruses
resource representing a document's body	covid:2530bf775255e8026438e91645aba95d0506928e#body_text
is schema:about of	named entity 'THERAPEUTIC' named entity 'IMMUNOGLOBULINS' named entity 'DRUG RESEARCH' named entity 'PURIFIED' named entity 'CHIMERIC' named entity 'MICE' named entity 'HORSES' named entity 'SUDAN' named entity 'SYSTEM' named entity 'FOUNDATION' named entity 'VIRUSES' named entity 'SUDV' named entity 'BACULOVIRUS' named entity 'RECOMBINANT' named entity 'IMMUNE RESPONSES' named entity 'VACCINE CANDIDATE' named entity 'LAY' named entity 'THESE' named entity 'SPECIFIC' named entity 'INFECTION' named entity 'DEVELOPMENT' named entity 'HORSE' named entity 'development' named entity 'Particle' named entity 'immunoglobulins' named entity 'lay a foundation' named entity 'Immune Responses' named entity 'PBS' named entity 'CD19' named entity 'Negative staining' named entity 'competent cells' named entity 'cytokines' named entity 'cellular immune responses' named entity 'antisera' named entity 'Academy of Military Sciences' named entity 'PBS' named entity 'goat' named entity 'VLPs' named entity 'Th2' named entity 'vaccine' named entity 'ammonium sulfate' named entity 'mice' named entity 'VLPs' named entity 'immunization' named entity 'China' named entity 'SUDV' named entity 'primary antibody' named entity 'SUDV' named entity 'VLPs' named entity 'serially diluted' named entity 'humoral immune response' named entity 'TMB' named entity 'IgG' named entity 'Sf9' named entity 'antiviral' named entity 'adjuvant' named entity 'Th1' named entity 'adjuvant' named entity 'VP40' named entity 'Dulbecco's modified Eagle's medium' named entity 'Thermo Scientific' named entity 'CD40' named entity 'inoculum' named entity 'VLPs' named entity 'PBS' named entity 'plasmid' named entity 'transmission electron microscopy' named entity 'immunization'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software